Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20390105 | 0.92 | SREBF2 (0.40) | SREBF2HPGDSCDK5CDK5R1CCNA2 | |
| SCHEMBL12681433 | 0.89 | SREBF2 (0.38) | SREBF2HPGDS | |
| SCHEMBL12681411 | 0.88 | SREBF2 (0.41) | SREBF2HPGDSMAPKAPK2 | |
| SCHEMBL12681448 | 0.86 | AAK1 (0.43) | SREBF2 | |
| SCHEMBL31341055 | 0.80 | RAB9A (0.46) | SREBF2HPGDSGSK3BDYRK1A | |
| SCHEMBL31340947 | 0.80 | HPGDS (0.47) | SREBF2HPGDSGSK3BDYRK1ACDK5 | |
| SCHEMBL31341058 | 0.79 | HPGDS (0.46) | SREBF2HPGDSGSK3BDYRK1ACDK5 | |
| SCHEMBL31340994 | 0.78 | CHEK1 (0.48) | SREBF2HPGDSGSK3BDYRK1ACDK5 | |
| SCHEMBL31341023 | 0.76 | CDK5 (0.44) | SREBF2HPGDSGSK3BDYRK1ACDK5 | |
| SCHEMBL31341012 | 0.75 | CDK5 (0.57) | SREBF2HPGDSCDK5CDK5R1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842813-B2 | for synthesis of erythromycin derivatives; reacting thionyl chloride with 6-hydroxylmethyl-nicotinic acid methyl ester to provide 6-chloromethyl-nicotinic acid methyl ester, chlorinating, reacting with ammonia or ammonium hydroxide, sulfiding | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | claimed |
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | claimed |
| US-7842813-B2 | for synthesis of erythromycin derivatives; reacting thionyl chloride with 6-hydroxylmethyl-nicotinic acid methyl ester to provide 6-chloromethyl-nicotinic acid methyl ester, chlorinating, reacting with ammonia or ammonium hydroxide, sulfiding | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842813-B2 | for synthesis of erythromycin derivatives; reacting thionyl chloride with 6-hydroxylmethyl-nicotinic acid methyl ester to provide 6-chloromethyl-nicotinic acid methyl ester, chlorinating, reacting with ammonia or ammonium hydroxide, sulfiding | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842813-B2 | for synthesis of erythromycin derivatives; reacting thionyl chloride with 6-hydroxylmethyl-nicotinic acid methyl ester to provide 6-chloromethyl-nicotinic acid methyl ester, chlorinating, reacting with ammonia or ammonium hydroxide, sulfiding | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| WO-2009137739-A1 | PROCESSES FOR THE PREPARATION OF O-[5-[4-AMINO-THIAZOL-2-YL]-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | THOP1, HPD, TH | SREBF2 4822/4885HPGDS 246/4885GSK3B 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.